Kaohsiung Medical University

Gwo-Jaw Wang

Mei-Ling Ho

Je-Ken Chang

Yin-Chih Fu

Cherng-Chyi Tzeng

Hui-Ting Chen

Chih-Kuang Wang

Kuang-Chan Hsieh

Yeh-Long Chen

Chung-Hwan Chen

Hui-Min David Wang

Yao-Hsien Wang

Yi-Ting Chou

Su-Shin Lee

Rajalakshmanan Eswaramoorthy

Shun-Cheng Wu

Ching-Ying Wu

Eswaramoorthy Rajalakshmanan

Yin-Chin Fu

A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function. 

Conformations of divergent peptides with mineral binding affinity

The present invention relates to a hydrophilic drug and &#x3b2;-tricalcium phosphate (&#x3b2;-TCP) coating on a surface area of biopolymer matrix to form a sustained release system. The present invention also provides a method for preparing a sustained release system, comprising providing a surface are of biopolymer matrix coated with a hydrophilic drug and &#x3b2;-TCP.

Sustained release systems and preparation method thereof

The present invention provides a biomaterial comprising a scaffold consisting of collagen, hyaluronic acid, and gelatin, which are cross-linked via ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDC) between any two of collagen, hyaluronic acid, and gelatin. The present invention further provides a method for preparing the biomaterial and a method for enhancing wound healing with the biomaterial.

Biomaterial for wound healing

The present invention provides a method for preparing a composition comprising porous ceramic, comprising the following steps: (a) synthesizing poly(N-isopropylacrylamide-co-methacrylic acid) (p(NIPAAM-MAA)) or similar thermo-response compound thereof; (b) mixing a dispersant with hydroxyapatite or calcium phosphate salt; (c) mixing the p(NIPAAM-MAA) of the step (a) or similar thermo-response compound thereof with water to obtain a hydrogel solution; (d) mixing the hydrogel solution of the step (c) and product of the step (b) to produce a mixture; (e) adding macromolecular particles to the mixture of the step (d) and stirring to produce a slurry; (f) filling the slurry of the step (e) into a template slot; and disposing the template slot filling with the slurry of the step (f) on a crucible, then proceeding high temperature sinter in a furnace to form the composition comprising porous ceramic.

Method for preparing composition comprising porous ceramic with thermo-response hydrogel

A method for locally controlled release of an effective amount of PTH(1-34) by a hyaluronic acid based hydrogel that can injected intra-articularly for the treatment of osteoarthritis is provided.

Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel

The present invention provides a method for producing a controlled release microsphere with mean average size greater than 50 &#x3bc;m, comprising preparing a water-in-oil (w/o) emulsion comprising an inner aqueous layer containing a pharmaceutically effective amount of a biologically active polypeptide with activity similar to parathyroid hormone, and an oil layer containing a polymer substance of poly(lactic-co-glycolic acid) (PLGA), then adding the w/o emulsion into aqueous polyvinyl alcohol (PVA) solution to form a water-in-oil-in-water (w/o/w) double emulsion and then desorbing the solvent in the oil layer. The present invention also provides a controlled release microsphere prepared by the method and use thereof.

Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres

A controlled release system and manufacturing method is provided. The method comprises providing a first aqueous solution containing a hydrophilic drug and an alkaline agent, providing an organic solution containing a hydrophobic molecule, providing a second aqueous solution containing a hydrophilic surfactant, mixing the first hydrophilic solution with the organic solution to form a first emulsion, and mixing the first emulsion with a second aqueous solution to form a second emulsion containing delayed-release microsphere.

Controlled release system and manufacturing method thereof

A method for treating early-stage osteoarthritis in an animal is provided. The method comprises delivery of a therapeutically effective amount of a parathyroid hormone (PTH) or a PTH derived substance to an affected joint cavity of the patient. Methods for inhibiting articular chondrocytes apoptosis and for inhibiting a degenerative process of articular chondrocytes in an afflicted animal are also provided.

Treatment of early-stage osteoarthritis

A method for treating and/or inhibiting arthritis is provided. The method includes administering an effective amount of a composition including a parathyroid hormone and a pharmaceutically acceptable carrier or salt to a subject with arthritis. Additionally, a method for inhibiting and/or rescuing terminal differentiation of cells is also provided.

Treatment of arthritis with parathyroid hormone

Disclosed herein is a three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes, as well as a process for preparing the same. The three-dimensional culture, which was found to mimic the biological characteristics of articular chondrocytes that undergo terminal differentiation in vivo, can be used as a tool in the studies of the molecular and cellular mechanisms of osteoarthritis, and in the screening of candidate drugs for use in treatment of a disorder associated with articular chondrocytes.

Three-dimensional culture containing human articular chondrocytes with induced terminal differentiation changes and preparation process and uses of the same

An isoxazole derivative is provided. The isoxazole derivative has following formula: 

Isoxazole derivatives and pharmaceutical compositions comprising the same

An isoflavone derivative is provided. The isoxazole derivative has following formula:  wherein Rand R, independently, include C-Calkyl optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy, and Rincludes hydrogen, hydroxy or C-Calkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis including an isoflavone derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Growing community of inventors

Kaohsiung, Taiwan

Gwo-Jaw Wang